DK1848813T3 - Aktivering af bakterielt glycolipid fra CD1D-begrænsede NKT-celler - Google Patents
Aktivering af bakterielt glycolipid fra CD1D-begrænsede NKT-cellerInfo
- Publication number
- DK1848813T3 DK1848813T3 DK06733921.8T DK06733921T DK1848813T3 DK 1848813 T3 DK1848813 T3 DK 1848813T3 DK 06733921 T DK06733921 T DK 06733921T DK 1848813 T3 DK1848813 T3 DK 1848813T3
- Authority
- DK
- Denmark
- Prior art keywords
- cd1d
- activation
- nkt cells
- restricted nkt
- bacterial glycolipid
- Prior art date
Links
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 title 1
- 229930186217 Glycolipid Natural products 0.000 title 1
- 230000004913 activation Effects 0.000 title 1
- 230000001580 bacterial effect Effects 0.000 title 1
- 210000000581 natural killer T-cell Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64815305P | 2005-01-28 | 2005-01-28 | |
| PCT/US2006/002781 WO2006083671A2 (en) | 2005-01-28 | 2006-01-26 | Bacterial glycolipid activation of cd1d-restricted nkt cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1848813T3 true DK1848813T3 (da) | 2013-07-15 |
Family
ID=36777772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06733921.8T DK1848813T3 (da) | 2005-01-28 | 2006-01-26 | Aktivering af bakterielt glycolipid fra CD1D-begrænsede NKT-celler |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9295722B2 (enExample) |
| EP (1) | EP1848813B1 (enExample) |
| JP (1) | JP5053101B2 (enExample) |
| AU (1) | AU2006211485B2 (enExample) |
| BR (1) | BRPI0607299A2 (enExample) |
| CA (1) | CA2593715C (enExample) |
| DK (1) | DK1848813T3 (enExample) |
| ES (1) | ES2423005T3 (enExample) |
| PL (1) | PL1848813T3 (enExample) |
| PT (1) | PT1848813E (enExample) |
| WO (1) | WO2006083671A2 (enExample) |
| ZA (1) | ZA200706208B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645873B2 (en) | 2003-03-20 | 2010-01-12 | The Scripps Research Institute | 6″-amino-6″-deoxygalactosylceramides |
| SI2056842T1 (sl) * | 2006-04-07 | 2013-02-28 | The Scripps Research Institute | Modificiran galaktosil-ceramid za zdravljenje kancerogenih obolenj |
| AU2007269299B2 (en) | 2006-06-30 | 2013-01-17 | Brigham Young University | Adjuvants and methods of use |
| JP2010523724A (ja) * | 2007-04-13 | 2010-07-15 | アカデミア シニカ | α−ガラクトシルセラミド類似体およびそれらの免疫療法剤としての使用 |
| US8916164B2 (en) | 2007-08-29 | 2014-12-23 | Abivax | Methods of enhancing adjuvaticity of vaccine compositions |
| AU2013202869B2 (en) * | 2007-11-07 | 2015-10-22 | Abivax | Increase of immune response and targeting by antigens and/or drug linkage |
| EP2058011A1 (en) | 2007-11-07 | 2009-05-13 | Wittycell | Nkt cell activating gycolipids covalently bound antigens and/or drug |
| EP2060252A1 (en) | 2007-11-19 | 2009-05-20 | Wittycell | New formulation of galactosylceramide derivatives |
| EP2231145B1 (en) | 2007-12-05 | 2014-09-17 | Wittycell | Use of glycosylceramides for enhancing the immune response to antigens |
| CN102215864A (zh) * | 2008-10-08 | 2011-10-12 | 威蒂赛尔公司 | 用于抗流感的疫苗组合物 |
| CA2753641C (en) | 2009-02-25 | 2014-09-16 | Supratek Pharma, Inc. | Bendamustine cyclopolysaccharide compositions |
| US8383663B2 (en) | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| US9764037B2 (en) * | 2012-12-06 | 2017-09-19 | Victoria Link Limited | Conjugate compounds |
| US9580758B2 (en) | 2013-11-12 | 2017-02-28 | Luc Montagnier | System and method for the detection and treatment of infection by a microbial agent associated with HIV infection |
| EP4138849A4 (en) * | 2020-04-23 | 2024-04-17 | The Regents of the University of California | CLEARANCE OF SENESCENT CELLS BY ACTIVATION OF INKT LYMPHOCYTES |
| WO2022129549A1 (en) * | 2020-12-18 | 2022-06-23 | L'oreal | Extract of bacteria of the genus sphingomonas |
| FR3117776B1 (fr) * | 2020-12-18 | 2024-03-08 | Oreal | Extrait de bactérie du genreSphingomonas |
| IL305579A (en) | 2021-03-01 | 2023-10-01 | Deciduous Therapeutics Inc | Compounds for activating invariant natural killer T cells and methods for use in eliminating inflammatory senescent cells |
| WO2024107463A1 (en) * | 2022-11-14 | 2024-05-23 | The Trustees Of Columbia University In The City Of New York | 7dw8-5 treatment for covid-19 and other virus-induced respiratory infections |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| TW261533B (enExample) | 1992-07-16 | 1995-11-01 | Kirin Brewery | |
| CA2147629C (en) | 1992-10-22 | 2005-03-22 | Koji Akimoto | Novel sphingoglycolipids and the use thereof |
| AU683653B2 (en) | 1993-04-15 | 1997-11-20 | Kirin Pharma Kabushiki Kaisha | Novel sphingoglycolipid and use thereof |
| CA2162478A1 (en) | 1993-05-14 | 1994-11-24 | Shawn A. Defrees | Sialyl lex analogues as inhibitors of cellular adhesion |
| CN1222293C (zh) | 1997-04-10 | 2005-10-12 | 麒麟麦酒株式会社 | 含有α－糖基神经酰胺的NKT细胞活化剂 |
| JP2001515868A (ja) * | 1997-09-12 | 2001-09-25 | ブライハム アンド ウイメンズ ホスピタル | Ｃｄ１制限免疫応答のための合成抗原 |
| AU2001252599A1 (en) | 2000-04-28 | 2001-11-12 | Orient Cancer Therapy Co., Ltd. | Remedies for cancer |
| US20020071842A1 (en) * | 2000-06-05 | 2002-06-13 | Gumperz Jenny E. | Soluble CD1 compositions and uses thereof |
| PT1297017E (pt) * | 2000-06-19 | 2012-09-04 | Gen Hospital Corp | Composições e métodos de anticorpos monoclonais e policlonais específicos para subpopulações de célula t |
| WO2001098317A2 (en) * | 2000-06-22 | 2001-12-27 | The Brigham And Women's Hospital, Inc. | Alpha-glycosylceramides for treating bacterial and fungal infections |
| EP1434859A2 (en) | 2001-07-25 | 2004-07-07 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
| KR100549866B1 (ko) | 2001-08-22 | 2006-02-08 | 고려대학교 산학협력단 | 암치료 및 예방 제제 |
| CN1578667A (zh) | 2001-11-06 | 2005-02-09 | 东方癌症治疗株式会社 | 抗癌组合物 |
| JP2005533057A (ja) * | 2002-06-13 | 2005-11-04 | ニューヨーク・ユニバーシティ | 合成ｃ−糖脂質、ならびに癌、感染性疾患および自己免疫疾患を処置するための合成ｃ−糖脂質の使用 |
| AU2003225891A1 (en) | 2003-03-20 | 2004-11-19 | Brigham Young University | 6"-amino-6"-deoxygalactosylceramides |
| US7645873B2 (en) | 2003-03-20 | 2010-01-12 | The Scripps Research Institute | 6″-amino-6″-deoxygalactosylceramides |
| GB0314682D0 (en) | 2003-06-24 | 2003-07-30 | Isis Innovation | Materials and methods relating to the modulation of T cell response to soluble antigen |
| US7998739B2 (en) | 2004-09-03 | 2011-08-16 | The Scipps Research Institute | Methods of activating NKT cells |
| SI2056842T1 (sl) | 2006-04-07 | 2013-02-28 | The Scripps Research Institute | Modificiran galaktosil-ceramid za zdravljenje kancerogenih obolenj |
| AU2007269299B2 (en) | 2006-06-30 | 2013-01-17 | Brigham Young University | Adjuvants and methods of use |
-
2006
- 2006-01-26 BR BRPI0607299-2A patent/BRPI0607299A2/pt not_active IP Right Cessation
- 2006-01-26 PL PL06733921T patent/PL1848813T3/pl unknown
- 2006-01-26 PT PT67339218T patent/PT1848813E/pt unknown
- 2006-01-26 JP JP2007553225A patent/JP5053101B2/ja not_active Expired - Fee Related
- 2006-01-26 CA CA2593715A patent/CA2593715C/en not_active Expired - Fee Related
- 2006-01-26 ES ES06733921T patent/ES2423005T3/es active Active
- 2006-01-26 WO PCT/US2006/002781 patent/WO2006083671A2/en not_active Ceased
- 2006-01-26 EP EP06733921.8A patent/EP1848813B1/en not_active Not-in-force
- 2006-01-26 AU AU2006211485A patent/AU2006211485B2/en not_active Ceased
- 2006-01-26 US US11/814,103 patent/US9295722B2/en not_active Expired - Fee Related
- 2006-01-26 DK DK06733921.8T patent/DK1848813T3/da active
-
2007
- 2007-07-26 ZA ZA200706208A patent/ZA200706208B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2423005T3 (es) | 2013-09-17 |
| BRPI0607299A2 (pt) | 2009-08-25 |
| AU2006211485B2 (en) | 2011-04-14 |
| EP1848813A2 (en) | 2007-10-31 |
| EP1848813B1 (en) | 2013-04-10 |
| US20080279894A1 (en) | 2008-11-13 |
| JP2008528608A (ja) | 2008-07-31 |
| WO2006083671A2 (en) | 2006-08-10 |
| PL1848813T3 (pl) | 2013-09-30 |
| AU2006211485A1 (en) | 2006-08-10 |
| JP5053101B2 (ja) | 2012-10-17 |
| WO2006083671B1 (en) | 2007-04-12 |
| CA2593715A1 (en) | 2006-08-10 |
| CA2593715C (en) | 2015-05-05 |
| ZA200706208B (en) | 2008-04-30 |
| PT1848813E (pt) | 2013-07-15 |
| EP1848813A4 (en) | 2008-07-09 |
| US9295722B2 (en) | 2016-03-29 |
| WO2006083671A3 (en) | 2007-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1848813T3 (da) | Aktivering af bakterielt glycolipid fra CD1D-begrænsede NKT-celler | |
| EP2178460A4 (en) | cartilage transplants | |
| PL2634242T3 (pl) | Ulepszony sposób hodowli komórek | |
| BRPI0816613A2 (pt) | novos derivados de oligossacarideos sulfatados | |
| EP2173353A4 (en) | Transplants | |
| BRPI0716881A2 (pt) | Composições tópicas | |
| BRPI0716762A2 (pt) | melhorias da cultura celular | |
| DE602006011777D1 (de) | Acrylhaftklebstoffzusammensetzung für polarisationsfolie | |
| CR9902A (es) | Drrivados de amida heterociclica utiles como microbiocidas | |
| EP1958592A4 (en) | intraocular lens | |
| EP2154906A4 (en) | SPEAKER SYSTEM | |
| DK1913135T3 (da) | Extracellulære polyhydroxyalkanoater frembragt af genetisk modificerede mikroorganismer | |
| DK2139936T3 (da) | Polyurethansammensætning indeholdende asymmetrisk dialdimin | |
| EP2245546A4 (en) | ASYNCHRONOUS REPLICATION | |
| EP2083933A4 (en) | IMPROVED MEMBRANE MODULE | |
| DK2027150T3 (da) | Allo-begrænsede peptid-specifikke t-celler | |
| BRPI0814572A2 (pt) | Célula de lítio | |
| DE602007008627D1 (de) | Zellkulturmedium | |
| BRPI0813726A2 (pt) | Célula de lítio | |
| EP1937307A4 (en) | SPECIFIC REMOVAL OF ACTIVATED IMMUNOCELLS | |
| DK1838295T3 (da) | Anthelmintisk sammensætning | |
| DE602006004859D1 (de) | Flüssigkristallines polymer enthaltende zusammensetzung | |
| FR2917971B1 (fr) | Composition amincissante | |
| DE502008000917D1 (de) | Lautsprecherbox | |
| SI1848813T1 (sl) | Aktiviranje bakterijskega glikopida s CD1D omenjenih NKT-celic |